Quantcast

Latest Synthetic Biologics Inc. Stories

2014-09-16 12:30:33

-- Mark Pimentel, M.D., of Cedars-Sinai Delivered Keynote Presentation on Mechanism of Action -- ROCKVILLE, Md., Sept. 16, 2014 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE MKT: SYN), a biotechnology company developing novel anti-infective biologic and drug programs targeting specific pathogens that cause serious infections and diseases, announced today the completion of the Company's Investor Day in New York which highlighted its irritable bowel syndrome (IBS) program, including...

2014-09-12 12:25:50

-- Company Expects to File IND to Support Clinical Trials in Mid-2015 -- ROCKVILLE, Md., Sept. 12, 2014 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE MKT: SYN), a biotechnology company developing novel anti-infective biologic and drug programs targeting specific pathogens that cause serious infections and diseases, announced today that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation to the Company's proprietary SYN-005 monoclonal antibody (mAb)...

2014-09-11 08:27:38

-- Conference Call Scheduled for Friday, September 12, 2014, at 9:15 a.m. EDT -- ROCKVILLE, Md., Sept. 11, 2014 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE MKT: SYN), a biotechnology company developing novel anti-infective biologic and drug candidates targeting specific pathogens that cause serious infections and diseases, announced today that it will host a an investor conference call on Friday, September 12, 2014, at 9:15 a.m. EDT. The conference call will highlight...

2014-09-10 12:29:04

-- Keynote Speaker: Mark Pimentel, M.D., FRCP(C), Director, GI Motility Program and Laboratory, Cedars-Sinai Medical Center; Chairman, Synthetic Biologics' C-IBS Clinical Advisory Board -- ROCKVILLE, Md., Sept. 10, 2014 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE MKT: SYN), a biotechnology company developing novel anti-infective biologic and drug candidates targeting specific pathogens that cause serious infections and diseases, announced today that its Investor Day to highlight...

2014-09-08 08:29:12

-- SYN-005 Neutralizing Antibody Combination Protects Against Pertussis in Murine and Non-Human Primate Models -- ROCKVILLE, Md., Sept. 8, 2014 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE MKT: SYN), a biotechnology company developing novel anti-infective biologic and drug programs targeting specific pathogens that cause serious infections and diseases, announced today that data from its novel SYN-005 program for the treatment of Pertussis were highlighted in an oral presentation...

2014-09-07 08:20:25

ROCKVILLE, Md., Sept. 7, 2014 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE MKT: SYN), a biotechnology company developing novel anti-infective biologic and drug programs targeting specific pathogens that cause serious infections and diseases, announced today preclinical data that further validate the Company's novel approach to preventing Clostridium difficile (C. difficile). The U.S. Centers for Disease Control has identified C. difficile as an "urgent public health threat," and it...

2014-09-03 08:32:42

ROCKVILLE, Md., Sept. 3, 2014 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of novel anti-infective biologic and drug candidates targeting specific pathogens that cause serious infections and diseases, announced today that Jeffrey Riley, CEO, is scheduled to present at the 16(th) Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC. Mr. Riley is scheduled to present at 10:25 a.m. (Eastern Time) on Tuesday,...

2014-09-02 08:29:18

-- Company Completes Final Preclinical Toxicology Study and Prepares to File Investigational New Drug (IND) in 2H 2014 -- ROCKVILLE, Md., Sept. 2, 2014 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of novel anti-infective biologic and drug candidates targeting specific pathogens that cause serious infections and diseases, announced today positive results from its final preclinical toxicology study of SYN-004. Per U.S. Food and Drug Administration (FDA)...

2014-08-28 08:27:37

-- Fujifilm's pAVEway(TM) Platform Demonstrated >25-fold Improvement in SYN-004 Expression Titers -- ROCKVILLE, Md., Aug. 28, 2014 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of novel anti-infective biologic and drug candidates targeting specific pathogens that cause serious infections and diseases, and FUJIFILM Diosynth Biotechnologies UK Limited (Fujifilm), announced today confirmation of exceptional results from the initial phase of cGMP manufacturing of...

2014-08-26 08:30:16

ROCKVILLE, Md., Aug. 26, 2014 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE MKT: SYN), a biotechnology company developing novel anti-infective biologic and drug programs targeting specific pathogens that cause serious infections and diseases, announced today that SYN-004, the Company's lead anti-infective product candidate for the prevention of the devastating effects of Clostridium difficile (C. difficile), will be presented at the Infectious Disease Week (IDWeek 2014(TM)) held by...


Word of the Day
grass-comber
  • A landsman who is making his first voyage at sea; a novice who enters naval service from rural life.
According to the OED, a grass-comber is also 'a sailor's term for one who has been a farm-labourer.'